Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Public market investors often have only 90 days to diligence an IPO using the S-1 filing. Crossover investors who engage with companies privately for years develop a deep, historical understanding of the business and management. This long-term context provides a significant informational advantage and allows for higher conviction.

Related Insights

Backing independent sponsors on a deal-by-deal basis is more than an investment strategy; it is an extended due diligence process. This approach provides deep, real-time insights into a manager's problem-solving skills under pressure, offering transparency that is impossible to achieve before a Fund I commitment.

In an information-poor credit market, H.I.G. gains its advantage by tapping its network of portfolio company CEOs and deal teams who have competed with or analyzed a target. This internal, proprietary insight provides a deeper level of diligence that independent firms cannot replicate, allowing for confident investment in troubled situations.

A compressed diligence process relies heavily on projections. A superior approach is building a relationship over 1-2 years, which allows an investor to witness the company's actual execution against its stated goals, providing far greater conviction than any financial model.

Company investor relations teams want stable, long-term shareholders. Funds known for 5-10 year holding periods become preferred partners for management, providing deeper insights and a research edge unavailable to short-term hedge funds or index funds.

Private credit allows investors to act like chefs—deeply involved from ingredient sourcing (diligence) to final creation (structuring). Liquid market investors are like food critics, limited to analyzing the finished product with restricted access to information, which increases risk.

David Craver asserts that being an active private market investor is an "imperative" for success in public markets. The research and insights gained from late-stage, pre-IPO companies provide crucial information that directly informs and strengthens a firm's public equity investment strategy in an interconnected landscape.

To win highly sought-after deals, growth investors must build relationships years in advance. This involves providing tangible help with hiring, customer introductions, and strategic advice, effectively acting as an investor long before deploying capital.

Traditional venture funds have a mandate to distribute shares post-IPO. A crossover investor can credibly promise a founder, 'I never have to sell your stock to get paid. If you execute, I can hold you forever.' This aligns the investor with the founder's long-term vision and offers stability.

In today's crowded market, the key PE differentiator is no longer financial engineering but the ability to identify and cultivate relationships with target companies months or years before a sale process. This provides the necessary time for deep diligence and strategic planning.

A successful biotech IPO isn't about attracting the public; it's about securing commitments from crossover investors beforehand. These investors must "bring their own beer to the party" by participating in the IPO. Their presence validates the company, stabilizes the offering, and is essential for attracting generalist funds later.